false
OasisLMS
zh-CN,en,fr,de,es
Catalog
Pain Core Curriculum Module 8: Buprenorphine for C ...
Presentation
Presentation
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Katie Fitzgerald-Jones, a nurse scientist at VA Boston, presents an in-depth overview of buprenorphine's role in chronic pain management, focusing on its formulations and clinical applications. Buprenorphine, a Schedule III partial opioid agonist with high receptor affinity and slow dissociation, offers effective analgesia with improved safety compared to full agonists, reducing risks like respiratory depression and opioid side effects. It is available in transdermal, buccal, and sublingual forms, with dosing tailored according to opioid tolerance and presence of opioid use disorder (OUD). Lower-dose formulations (transdermal and buccal) suit opioid-naive patients or those on less than 100 mg morphine equivalents daily, while the sublingual form is preferred for OUD or higher opioid tolerance. Initiation requires careful strategies—traditional initiation with observed withdrawal or low-dose initiation to prevent precipitated withdrawal. Clinical cases illustrate buprenorphine's benefits in older adults, patients with complex comorbidities, cancer pain, and perioperative management, emphasizing its role in enhancing pain control and safety, minimizing opioid misuse, and maintaining OUD treatment stability. National guidelines, including the CDC and VA, recommend buprenorphine as the opioid of choice for chronic pain requiring around-the-clock therapy. Continuation of buprenorphine in the perioperative period and serious illness is critical to prevent destabilization. Resources such as the PCSS MOUD Mentoring Program support clinicians in buprenorphine care.
Keywords
buprenorphine
chronic pain management
partial opioid agonist
transdermal formulation
buccal formulation
sublingual formulation
opioid use disorder
opioid tolerance
perioperative pain control
×